Copyright ©The Author(s) 2020.
World J Hepatol. May 27, 2020; 12(5): 239-252
Published online May 27, 2020. doi: 10.4254/wjh.v12.i5.239
Table 1 Characteristics of the studies included in the network meta-analysis
Therapy/controlRef.YrDosage of therapyControlMean follow-upHistory of SBP/%ITT/PPSBP diagnosis criterian (total)Therapy
nDeveloped SBPDeaths/transplantnDeveloped SBPDeath/transplant
Ciprofloxacin vs placeboTerg et al[45]2008Ciprofloxacin 500 mg dailyPlacebo7.6-7.8 moExcludedITTAscites PMN > 250/mm3100502/506/50507/5015/50
Norfloxacin vs placeboGinés et al[46]1990Norfloxacin 400 mg dailyPlacebo6.4 moIncluded/20.0%ITTAbdominal pain, fever, ascites PMN > 350/mm380405/407/404014/4011/40
Norfloxacin vs no treatmentNovella et al[47]1997Norfloxacin 400 mg dailyNo treatment43 wkExcludedITTAscites PMN > 250/mm3, positive ascitic fluid culture109561/5613/56539/5316/53
Norfloxacin vs placeboGrangé et al[48]1998Norfloxacin 400 mg dailyPlacebo6 moExcludedITTAscites PMN > 250/mm3, positive ascitic fluid culture107530/538/53545/5411/54
Norfloxacin vs placeboFernández et al[49]2007Norfloxacin 400 mg dailyPlacebo12 moExcludedITTAscites PMN > 250/mm368352/3516/353310/3319/33
Norfloxacin vs placeboMoreau et al[50]2018Norfloxacin 400 mg dailyPlacebo6 moIncluded/88.3%ITTAscites PMN > 250/mm329114410/14436/14414717/14742/147
Norfloxacin vs ciprofloxacinYim et al[51]2018Norfloxacin 400 mg dailyCiprofloxacin 750 mg weekly12 moIncluded/88.7%ITT/PPAscites PMN > 250/mm3124624/5515/62623/5716/62
Rifaximin vs norfloxacinMostafa et al[34]2015Rifaximin 800 mg dailyNorfloxacin 400 mg daily6 moIncluded/100%ITTAscites PMN > 250/mm370400/400/40305/300/30
Rifaximin vs norfloxacinElfert et al[35]2016Rifaximin 1200 mg dailyNorfloxacin 400 mg daily6 moIncluded/ 100%ITT/PPAscites PMN > 250/mm32621314/10318/13113113/9232/131
Rifaximin vs norfloxacinAssem et al[33]2016Rifaximin 1100 mg dailyNorfloxacin 400 mg daily6 moExcludedITT/PPAscites PMN > 250/mm3334828/648/827813/5711/78
Trimethoprim-sulfamethoxazole vs no treatmentSingh et al[52]1995TMP-SMX 160/800 mg 5 d per weekNo treatment90 dIncluded/73.3%ITTAscites PMN > 250/mm360301/302/30308/306/30
Trimethoprim-sulfamethoxazole vs norfloxacinAlvarez et al[53]2005TMP-SMX 160/800 mg 5 d per weekNorfloxacin 400 mg daily163-182 dIncluded/38.6%NAAscites PMN > 250/mm357254/255/25323/327/32
Trimethoprim-sulfamethoxazole vs norfloxacinLontos et al[54]2014TMP-SMX 160/800 mg dailyNorfloxacin 400 mg daily208-251 dIncluded/26.2%ITTAscites PMN > 250/mm380402/4022/40402/4018/40
Table 2 JADAD and Cochrane meta-analysis bias scores
Study1 Was the study describ-ed as randomiz-ed?2 Was the randomi-zation scheme describ-ed and appropriate?3 Was the study describ-ed as double-blind?4 Was the method of double blinding appropri-ate?5 Was there a descrip-tion of dropouts and withdra-wals?Total JADAD ScoreSequen-ce genera-tion (for arm randomi-zation)Alloca-tion conceal-edBlinding of outcom-esIncomple-te outcome data address-edITTSample size calcula-tion
Ginés et al[46]ONAOOO4XXOOOO
Singh et al[52]ONAXNAX1??X?OX
Novella et al[47]ONAXNAO2??X?OX
Grangé et al[48]ONAONAO3???OOO
Alvarez et al[53]ONAXNAX1OOX??X
Fernández et al[49]OOONAO4OOOOOO
Terg et al[45]OOONAO4OOOOOO
Lontos et al[54]OOXNAO3OXXOOO
Mostafa et al[34]ONAXNAX1OXX?OO
Elfert et al[35]OOXNAO3OXX?OO
Assem et al[33]OOXNAO3OXX?OO
Yim et al[51]OOXNAO3OXX?OO
Moreau et al[50]OOOOO5OOOOOO